← ANALYST RATINGS · TIPRANKS
Hemab Therapeutics Holdings, Inc. (COAG): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $62.50, the highest $70.00, the lowest $56.00. The average is +107.8% from the last price of $30.07.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Name not given | — | $70.00 | Buy | +132.8% | Initiated | 15.10.26on TipRanks Oct 16 06:20 | +8.3%next day −6.4% | ↗ |
| Michael King★★★★★★★★★★#11053 · hits 39% · avg −2.3% | Rodman & Renshaw | $56.00 | Buy | +86.2% | Initiated | 12.10.26on TipRanks 07:45 | −3.8%next day −1.9% | ↗ |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $55.00 → $64.00+16.4% | Buy | +112.8% | Reiterated | 12.08.26on TipRanks 09:56 | +3.1%next day +0.2% · 5 days −3.0% | ↗ |
| Emily Bodnar★★★★★★★★★★#2140 · hits 39% · avg +7.2% | H.C. Wainwright | $52.00 → $60.00+15.4% | Buy | +99.5% | Assigned | 11.08.26on TipRanks 11:54 | +4.1%next day +3.1% · 5 days +1.8% | ↗ |
| Richard Law CFA★★★★★★★★★★#3237 · hits 50% · avg +9.1% | Goldman Sachs | $36.00 → $46.00+27.8% | Buy | +53.0% | Reiterated | 13.07.26on TipRanks Jul 14 08:55 | +4.7%next day +9.3% · 5 days +26.0% | ↗ |
| Maury Raycroft★★★★★★★★★★#1326 · hits 44% · avg +12.0% | Jefferies | $39.00 → $47.00+20.5% | Buy | +56.3% | Reiterated | 13.07.26on TipRanks 09:12 | +4.7%next day +9.3% · 5 days +26.0% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $50.00 | Buy | +66.3% | Initiated | 26.05.26on TipRanks Jun 3 07:31 | +6.9%next day +2.7% · 5 days −2.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Hemab Therapeutics Holdings, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $54.25 at a price of $30.84 (+75.9%); now: $62.50 at $30.07 (+107.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 4 | 4 | 2 | 0 | 2 |
| Buy | 2 | 4 | 8 | 8 | 6 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · General
About Hemab Therapeutics Holdings, Inc.
- CEO: Benny Sorensen
- Employees: 59
- 101 Main Street, Cambridge, MA, 02142, US
- www.hemab.com
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 66 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗